FibrosisLab
Article
Published: 2026-03-12

The Frontline of Liver Anti-Fibrotic Drug Development 2026: Post-Resmetirom Era

A deep dive into the 2026 MASH pipeline focusing on direct anti-fibrotic efficacy, exploring FGF21 analogues, multi-receptor agonists, and strategies for preclinical validation.

Reviewed by Fibrosis-Inflammation Lab Scientific Team

Introduction

In the Spring of 2024, Madrigal Pharmaceuticals' THR-β agonist Resmetirom (Rezdiffra) received accelerated FDA approval, marking a historic milestone as the world's first approved treatment for MASH (Metabolic dysfunction-associated steatohepatitis). The MASH space, long considered a massive area of unmet medical need, has finally entered its commercialization phase.

However, while Resmetirom is excellent at resolving steatosis and ballooning, its ability to dramatically reverse pre-existing severe fibrosis is inherently limited. Consequently, the primary focus of MASH drug development for 2025-2026 has completely shifted toward "Anti-fibrotic efficacy"—how to directly and powerfully reverse liver fibrosis.

This article explores the most promising "Liver Anti-fibrotics" in the 2026 pipeline and the preclinical evaluation strategies required to validate them.

1. The Paradigm Shift Brought by Resmetirom

The achievement of the primary endpoints in Resmetirom's Phase 3 MAESTRO-NASH trial presented two critical facts to the industry1:

  1. Resolving steatosis prevents fibrosis progression: If lipotoxicity (the root cause of MASH) is reduced early, fibrosis worsening is significantly halted.
  2. However, "Reversal" of existing advanced fibrosis (F3) remains difficult: Despite approval, only about 25% of the treated patients achieved the fibrosis improvement endpoint. For the remaining 75%, fibrosis remained unchanged or worsened.

Given these outcomes, the future of MASH treatment will likely adopt a personalized combination strategy: controlling early stages (F1-F2) with metabolic modifiers (Resmetirom or GLP-1 RAs), while targeting advanced stages (F3-F4) with drugs that possess powerful, direct "anti-fibrotic mechanisms"—either alone or in combination.

2. 2026 Spotlight: Leading Anti-Fibrotic Mechanisms (MoA)

Currently, two major target classes are demonstrating intense efficacy in resolving fibrosis, going beyond mere weight loss or insulin sensitization.

A. FGF21 Analogues (Fibroblast Growth Factor 21)

FGF21 is an endocrine hormone that regulates metabolism in the liver and adipose tissue. It not only improves insulin sensitivity via adiponectin secretion but also exerts direct anti-fibrotic effects by suppressing Hepatic Stellate Cell (HSC) activation.

  • Efruxifermin (Akero Therapeutics): An Fc-FGF21 fusion protein. In the Phase 2b HARMONY trial, approximately 41% of treated patients achieved at least a one-stage improvement in fibrosis, decisively beating the placebo (20%)2. Trials targeting compensated cirrhosis (F4) are currently underway.
  • Pegozafermin (89bio): A pegylated FGF21 analogue. The Phase 2b ENLIVEN trial reported that up to 27% of F2-F3 patients achieved both fibrosis improvement and MASH resolution3.

👉 Potential & Challenges: While the direct anti-fibrotic effect is incredibly strong, key challenges for widespread adoption include its injectable administration route and tolerability issues related to blood pressure and the GI tract.

B. GLP-1 / GCG / GIP Multi-Agonists

Weight-loss drugs like Semaglutide and Tirzepatide improve MASH pathology, but fibrosis "reversal" takes considerable time. To accelerate this, "multi-agonists" are rising to prominence. By simultaneously stimulating the glucagon (GCG) receptor, these drugs forcefully increase hepatic lipid metabolism, clearing the way to relieve fibrotic pressure.

  • Survodutide (Boehringer Ingelheim): A dual GLP-1/GCG agonist. In its Phase 2 trial, up to 52% of patients across dose groups (compared to 26% for placebo) demonstrated fibrosis improvement. This exceptionally strong anti-fibrotic effect for an incretin-class drug astonished the industry4. Phase 3 trials are actively progressing.

3. The Preclinical Hurdle: Proving Anti-Fibrotic Efficacy

The common requirement for these next-generation pipelines is the ability to "melt" or reverse existing fibrosis. For pharma and biotech companies entering this market, they must prove in the preclinical (animal model) stage that their compound possesses a stronger "anti-fibrotic power" than existing agents like Resmetirom.

To achieve this, the following evaluation strategies are indispensable:

  1. Selecting the Correct Animal Model: While simple weight-loss drugs can be tested in the GAN DIO model, rapidly screening for direct fibrotic reversal often requires Proof of Concept (PoC) in accelerated fibrosis models such as the CDA-HFD model.
  2. Highly Sensitive Quantitative Evaluation: Relying solely on visual scoring by pathologists (e.g., NAS) is no longer sufficient. Providing absolute quantitative proof of collagen reduction through Sirius Red Staining Image Analysis (% Area) and biochemical Hydroxyproline Assays is becoming a mandatory package for advancing to Phase 2.

4. Conclusion: Toward the Next Frontier of MASH Treatment

The approval of Resmetirom is not the "finish line" for the MASH market; it is merely the starting line. Beyond 2026, the developmental spotlight shifts entirely towards "drugs that can safely and powerfully reverse progressive F3/F4 fibrosis."

To win this fierce pipeline race, establishing the right "model selection" and "quantitative evaluation systems" to flawlessly prove your compound's anti-fibrotic Mechanism of Action (MoA) during the early preclinical stages is absolutely critical.

Through our CRO partnerships, we provide comprehensive support to accelerate your anti-fibrotic projects, from procuring MASH-specific animal models to conducting fully outsourced quantitative evaluations.

References & Clinical Trials

1. Harrison SA, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497-509. PubMed 2. Harrison SA, et al. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nat Med. 2021;27(7):1262-1271. PubMed 3. Loomba R, et al. Pegozafermin in Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial. N Engl J Med. 2023;389(11):998-1008. PubMed 4. Boehringer Ingelheim Press Release. "Survodutide Phase II trial shows 83% of adults treated for MASH achieved statistically significant improvement." (2024)